GlassScriptPhysician profile
Thomas B Tucker
NPI 1982648820
$1,977.30
in general payments reported to CMS, 2019-2025
25 companies · $54.98 in 2025
The $54.98 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.68 · 2020: $11.75 · 2021: $25.85 · 2022: $839 · 2023: $798 · 2024: $166 · 2025: $54.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968 · Education: $51.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.69 |
| Education | $51.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $525.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $244.17 | 2023-2024 | Imfinzi, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $167.05 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $127.13 | 2022-2023 | Fotivda |
| Sobi, INC | $76.24 | 2022-2023 | |
| Abbvie INC. | $69.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $64.29 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $63.59 | 2022-2023 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $59.25 | 2022-2023 | Injectafer |
| Glaxosmithkline, LLC. | $55.65 | 2022-2023 | Ojjaara |
| Incyte Corporation | $50.61 | 2023 | Jakafi |
| Celgene Corporation | $49.53 | 2022-2023 | Pomalyst |
| Janssen Biotech, INC. | $48.54 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Cti Biopharma Corp. | $43.92 | 2022-2023 | Vonjo |
| Takeda Pharmaceuticals U.S.A., INC. | $42.52 | 2023 | Ninlaro, Iclusig |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.04 | 2023 | |
| Eisai INC. | $37.48 | 2022-2023 | |
| Taiho Oncology, INC. | $37.33 | 2023 | |
| Adc Therapeutics America, INC. | $36.33 | 2023-2024 | |
| Puma Biotechnology, INC. | $36.14 | 2023-2024 | |
| Pfizer INC. | $30.65 | 2025 | |
| Amgen INC. | $27.32 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.